It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Objective: To describe the implementation of a multi-step antimicrobial stewardship program in a haemato-oncology and stem cell transplantation program unit. Methods: Pre-post quasi-experimental study with two interrupted time-series analyses, conducted between 01/01/2019 and 31/12/2022 in the Paediatric Haemato-Oncology Unit of the Padua Paediatric Hospital. The interventions were: (1) 02/2020: dissemination of febrile neutropenia clinical pathways, (2) April 2021: provision of the clinical pathways via a customized App (Firstline.org) and implementation of a twice-a-week prospective audit and feedback. The main outcome was antibiotic consumption measured by days of administered therapy (DOTs)/1000 patients’ days for all antibiotics and most used molecules. Results: The first intervention (clinical pathways) resulted in a decrease in the overall antibiotic use by the haemato-oncology unit, with an abrupt reduction of 3-gen cephalosporins in favor of piperacillin-tazobactam, as indicated by the clinical pathways. Meropenem and glycopeptide use did not vary. The second intervention (antimicrobial stewardship) further decreased total antibiotic consumption, and a significant decline in meropenem, amikacin, and glycopeptides was achieved. Conclusions: Multi-step stewardship based on guidelines dissemination, multidisciplinary team intervention and collaboration (“handshake” stewardship) was highly effective in optimizing guidelines adherence and reducing overprescriptions in a fragile patient cohort.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Padova, Division of Paediatric Infectious Diseases, Department of Women’s and Children’s Health, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
2 Padua University Hospital, Paediatric Haematology, Oncology and Stem Cell Transplant, Padua, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
3 Azienda Ospedale-Università di Padova, Hospital Pharmacy Unit, Padua, Italy (GRID:grid.411474.3) (ISNI:0000 0004 1760 2630)
4 University of Verona, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Clinic, Verona, Italy (GRID:grid.5611.3) (ISNI:0000 0004 1763 1124)
5 Padua University Hospital, Microbiology and Virology Unit, Padua, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
6 University of Verona, Division of Infectious Diseases, Department of Diagnostic and Public Health, Verona, Italy (GRID:grid.5611.3) (ISNI:0000 0004 1763 1124)
7 University of Padova, Division of Paediatric Haematology, Oncology and Stem Cell Transplant, Department for Women’s and Children’s Health, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)